Verflixt! Es sieht so aus, als wenn Sie einen veralteten Browser benutzen. Wir empfehlen Ihnen dringend Ihren Browser zu aktualisieren.
Weitere Informationen über Browser und Updates finden Sie hier

LabPMM GmbH

Laboratory for Personalized Molecular Medicine (LabPMM), a fully owned subsidiary of Invivoscribe, is CLIA- and CAP-accredited reference laboratory that provides services focused on Personalized Molecular Medicine™, Personalized Molecular Diagnostics™, and biomarker testing. LabPMM has testing facilities in San Diego, California (LabPMM LLC) and Martinsried, Germany (LabPMM GmbH). These are the only clinical laboratories outside of Japan licensed to perform FLT3 biomarker testing and the only laboratories in the world licensed to determine the mutation status of both FLT3 and NPM1.

Invivoscribe Technologies, Inc., with headquarters in San Diego, California, is a leading provider of clinically validated personalized molecular diagnostics. The company and its subsidiaries provide one stop comprehensive care for patients in over 50 countries. Invivoscribe's portfolio of products include a comprehensive selection of PCR-based gene rearrangement, chromosome translocation, and gene mutation testing reagents and controls for the identification, classification and monitoring of leukemia, lymphomas and other lymphoproliferative diseases. Products include CE-marked IVD products for use outside North America, as well as a wide selection of Analyte Specific Reagents (ASRs), Research Use Only and General Laboratory Reagents.

Details


Adresse:
LabPMM GmbH

Bunsenstraße 7A
82152 Martinsried/Planegg
Deutschland
Arbeitsgebiet:
Forschung & Entwicklung
Klinik & Praxis
Produktion
Sonstige Tätigkeitsfelder
Vertrieb
Expansion:
international
Webseite:
Mitarbeiteranzahl:
51-500